Patents by Inventor Mohammed Kazim PANJWANI

Mohammed Kazim PANJWANI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF A CANINE CD20 POSITIVE DISEASE OR CONDITION USING A CANINE CD20-SPECIFIC CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20220168351
    Abstract: The present invention relates to compositions and methods for the treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor. One aspect includes a modified canine T cells and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity in canine.
    Type: Application
    Filed: August 31, 2021
    Publication date: June 2, 2022
    Inventors: Nicola MASON, Daniel J. POWELL, JR., Mohammed Kazim PANJWANI, Jenessa SMITH
  • Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor
    Patent number: 11116795
    Abstract: The present invention relates to compositions and methods for the treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor. One aspect includes a modified canine T cells and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity in canine.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: September 14, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Nicola Mason, Daniel J. Powell, Jr., Mohammed Kazim Panjwani, Jenessa Smith
  • TREATMENT OF A CANINE CD20 POSITIVE DISEASE OR CONDITION USING A CANINE CD20-SPECIFIC CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20190350972
    Abstract: The present invention relates to compositions and methods for the treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor. One aspect includes a modified canine T cells and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity in canine.
    Type: Application
    Filed: July 8, 2016
    Publication date: November 21, 2019
    Inventors: Nicola MASON, Daniel J. POWELL, Jr., Mohammed Kazim PANJWANI, Jenessa SMITH